PREVENIR 4 - Persistence of evidence-based medical therapies over time in patients monitored by cardiologists after a first recent ACS 
Head :
Amelineau Élisabeth, Bristol-Myers Squibb
Schmidely Nathalie, Bristol-Myers Squibb
Schmidely Nathalie, Bristol-Myers Squibb
Last update : 09/05/2017 | Version : 2 | ID : 138
| General | |
| Identification | |
| Detailed name | Persistence of evidence-based medical therapies over time in patients monitored by cardiologists after a first recent ACS |
| Sign or acronym | PREVENIR 4 |
| CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation | CNIL N°833542 version 8 |
| General Aspects | |
| Medical area |
Cardiology |
| Health determinants |
Medicine |
| Keywords | secondary prevention, persistence, care |
| Scientific investigator(s) (Contact) | |
| Name of the director | Amelineau |
| Surname | Élisabeth |
| Address | 3, rue J. Monier - 92500 Rueil Malmaison |
| Phone | +33 (0)1 58 83 60 00 |
| elisabeth.amelineau@bms.com | |
| Unit | Bristol-Myers Squibb |
| Name of the director | Schmidely |
| Surname | Nathalie |
| Address | 3, rue J. Monier - 92500 Rueil Malmaison |
| Phone | +33 (0)1 58 83 60 00 |
| nathalie.schmidely@bms.com | |
| Unit | Bristol-Myers Squibb |
| Collaborations | |
| Funding | |
| Funding status |
Private |
| Details | Bristol-Myers Squibb France |
| Governance of the database | |
| Sponsor(s) or organisation(s) responsible | Bristol-Myers Squibb France (BMS) |
| Organisation status |
Private |
| Additional contact | |
| Main features | |
| Type of database | |
| Type of database |
Study databases |
| Study databases (details) |
Not-repeated cross-sectional studies (except case control studies) |
| Database recruitment is carried out by an intermediary |
A selection of health institutions and services |
| Database recruitment is carried out as part of an interventional study |
No |
| Additional information regarding sample selection. | random sampling in clusters. |
| Database objective | |
| Main objective | Describe the persistence of secondary prevention therapeutics, between 3 and 18 months after hospitalization for a first acute coronary syndrome (ACS), in patients monitored by private or hospital cardiologists |
| Inclusion criteria | M/F >=18 years, outpatient seen in cardiology consultation, hospitalized in 2005 for a first ACS |
| Population type | |
| Age |
Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years) Great age (80 years and more) |
| Population covered |
Sick population |
| Gender |
Male Woman |
| Geography area |
National |
| Detail of the geography area | Metropolitan France |
| Data collection | |
| Dates | |
| Date of first collection (YYYY or MM/YYYY) | 2006 |
| Date of last collection (YYYY or MM/YYYY) | 2007 |
| Size of the database | |
| Size of the database (number of individuals) |
[1000-10 000[ individuals |
| Details of the number of individuals | 1801 |
| Data | |
| Database activity |
Data collection completed |
| Type of data collected |
Clinical data Biological data |
| Clinical data (detail) |
Direct physical measures |
| Biological data (detail) | total cholesterol, HDL, LDL, Triglycerides, glycemia |
| Presence of a biobank |
No |
| Health parameters studied |
Health care consumption and services |
| Care consumption (detail) |
Medicines consumption |
| Procedures | |
| Data collection method | Paper CRF |
| Participant monitoring |
No |
| Links to administrative sources |
No |
| Promotion and access | |
| Promotion | |
| Link to the document | http://www.ncbi.nlm.nih.gov/pubmed/?term=PREVENIR+AND+Amelineau+E[Author] |
| Access | |
| Terms of data access (charter for data provision, format of data, availability delay) | Publications |
| Access to aggregated data |
Access on specific project only |
| Access to individual data |
Access on specific project only |
